Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Abivertinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sorrento Announces Positive Phase IIa Study Results of Abivertinib
    Sorrento Announces Positive Phase IIa Study Results of Abivertinib

    05 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/05/2699555/0/en/Sorrento-Announces-Positive-Phase-IIa-Study-Results-of-Abivertinib-for-the-Treatment-of-Relapsed-Refractory-Marginal-Zone-Lymphoma-R-R-MZL-and-Its-Plan-for-a-Pivotal-Phase-III-Stud.html

    GLOBENEWSWIRE
    05 Jul 2023
    Share Share
    Sorrento Announces Trial Results as Assessed by an IRC of Abivertinib
    Sorrento Announces Trial Results as Assessed by an IRC of Abivertinib

    23 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/23/2503048/0/en/Sorrento-Announces-Significant-Positive-Pivotal-Trial-Results-as-Assessed-by-an-Independent-Review-Committee-IRC-With-Matured-Long-Term-Over-Three-Years-Follow-Up-Data-of-Abivertin.html

    GLOBENEWSWIRE
    23 Aug 2022
    Share Share
    FDA Clears Sorrento's Phase 2/3 Study for Abivertinib in Severe Pneumonia
    FDA Clears Sorrento's Phase 2/3 Study for Abivertinib in Severe Pneumonia

    31 Mar 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/03/31/2413934/0/en/Sorrento-Reports-FDA-Clearance-for-the-Commencement-of-a-Phase-2-3-Study-for-Abivertinib-in-Treatment-of-Hospitalized-Patients-With-Severe-Pneumonia-Due-to-COVID-19.html

    GLOBENEWSWIRE
    31 Mar 2022
    Share Share
    Sorrento Announces Encouraging Results From Two Ph2 Studies of Abivertinib
    Sorrento Announces Encouraging Results From Two Ph2 Studies of Abivertinib

    27 Oct 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/10/27/2322090/0/en/UPDATE-Sorrento-Announces-Encouraging-Results-From-Two-Phase-2-Studies-of-Abivertinib-For-Treatment-Of-Hospitalized-Severe-COVID-19-Patients.html

    GLOBENEWSWIRE
    27 Oct 2021
    Share Share
    Sorrento Announces Encouraging Results From Two Phase 2 Studies
    Sorrento Announces Encouraging Results From Two Phase 2 Studies

    27 Oct 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/10/27/2322062/0/en/Sorrento-Announces-Encouraging-Results-From-Two-Phase-2-Studies-of-Abivertinib-For-Treatment-Of-Hospitalized-Severe-COVID-19-Patients.html

    GLOBENEWSWIRE
    27 Oct 2021
    Share Share
    Sorrento Announces Phase 2 Abivertinib Studies Have Completed Patient Enrollment
    Sorrento Announces Phase 2 Abivertinib Studies Have Completed Patient Enrollment

    22 Jun 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/06/22/2251061/0/en/Sorrento-Announces-Phase-2-Abivertinib-Clinical-Studies-Have-Completed-Patient-Enrollment-in-USA-and-Brazil-with-Top-Line-Clinical-Data-Expected-End-of-3Q21.html

    GLOBENEWSWIRE
    22 Jun 2021
    Share Share